A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · HEALTH SERVICES RESEARCH · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 20
- Population
- ALL · 18 Years to 50 Years
- Duration
- 2026-09-30 to 2026-12-30
- Intervention
- PAN-90806 Ophthalmic Solution; Vehicle Ophthalmic Solution
- Comparator
- Vehicle Eye Drops, 0mg/mL
- Outcomes measured
- Corneal endothelial cell examination (density(cells/mm2) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); Corneal endothelial cell examination (coefficient of variation(% of variation in total endothelial cell size )) — Day-1…; Corneal endothelial cell examination(proportion of hexagonal cells(%)) — Day-14~Day -1, and Day 9 (set Day 0 as the day…; Central corneal thickness (μm) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); sodium fluorescein staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day…; Conjunctival lissamine green staining score of the cornea (NEI scale for the score) — Day-14~Day -1, Day 2, Day 4, Day…; Best corrected visual acuity(National standard logarithmic eye chart of China) — Day-14~Day -1, Day 2, Day 4, Day 6 and…; intraocular pressure measurements(mmHg) — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitaliz…; slit-lamp biomicroscopy — Day-14~Day -1, Day 2, Day 4, Day 6 and Day 9 (set Day 0 as the day hospitalized); non-dilated retinal photography — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); The incidence of adverse events — Day 1~Day 9; The severity of adverse events — Day 1~Day 9; blood pressure (using the portable blood pressure monitor, mmHg) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospi…; Pulse (using the portable blood pressure monitor, beats per minute (BPM)) — Day-14~Day -1, and Day 9 (set Day 0 as the…; Body temperature (Body temperature detection using infrared ear thermometer, ℃) — Day-14~Day -1, and Day 9 (set Day 0 a…; physical examination — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); electrocardiogra (Heart rate, PR interval(ms), QRS time limit(ms), QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set…; electrocardiogra (Heart rate) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); electrocardiogra (PR interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized); electrocardiogra (QT/QTc interval(ms)) — Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.